Aktienanalyse zu Cytokinetics Inc (CYTK)CYTKCytokinetics Inc

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Cytokinetics Inc is currently not a strong buy due to its recent price decline and negative financial indicators, despite a favorable analyst outlook. The current price is $61.23, with a forward P/E ratio of 117.65, which indicates high expectations for future earnings. However, the RSI is at 34.86, suggesting the stock is oversold, which could present a buying opportunity if the fundamentals improve. The main risk is the negative net income reported at -198,762,000 USD for Q2 2026, indicating ongoing financial struggles.

8 analysts cover CYTK: 8 rate it Buy, 0 Hold and 0 Sell. The average price target is 89.33.